ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ALEC Alector Inc

5.50
0.06 (1.10%)
21 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Alector Inc NASDAQ:ALEC NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.06 1.10% 5.50 5.12 5.81 5.60 5.31 5.48 614,293 01:00:00

Alector to Participate at the BofA Securities 2022 Healthcare Conference

04/05/2022 12:00pm

GlobeNewswire Inc.


Alector (NASDAQ:ALEC)
Historical Stock Chart


From May 2021 to May 2024

Click Here for more Alector Charts.

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Thursday, May 12, 2022, at 11:20 a.m. PT.

A live webcast of the fireside chat will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. A replay will be available on the Alector website for 90 days following the event.

About AlectorAlector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable the rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and target genetically defined patient populations in frontotemporal dementia and Alzheimer’s disease. This scientific approach is also the basis for the company’s immuno-oncology programs. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

Contacts:

1AB (media)Dan Budwick973-271-6085dan@1abmedia.com 

Argot Partners (investors)Eric Kasper/Carrie McKimArgot Partners212.600.1902alector@argotpartners.com 

1 Year Alector Chart

1 Year Alector Chart

1 Month Alector Chart

1 Month Alector Chart

Your Recent History

Delayed Upgrade Clock